Is Osimertinib a targeted drug?

Osimertinib (Osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) oral targeted drug. It is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) if the tumor's EGFR expression is positive for the T790M mutation as detected by a U.S. Food and Drug Administration (FDA)-approved test and has progressed after treatment with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of NSCLC patients have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations in tumor cells. It is usually used when patients develop drug resistance or are unable to tolerate other treatments.